Burska Agata, Boissinot Marjorie, Ponchel Frederique
Leeds Institute of Rheumatic and Musculoskeletal Medicine, The University of Leeds, Leeds, UK.
Leeds Institute of Cancer and Pathology Research, The University of Leeds, Leeds, UK.
Mediators Inflamm. 2014;2014:545493. doi: 10.1155/2014/545493. Epub 2014 Mar 9.
RA is a complex disease that develops as a series of events often referred to as disease continuum. RA would benefit from novel biomarker development for diagnosis where new biomarkers are still needed (even if progresses have been made with the inclusion of ACPA into the ACR/EULAR 2010 diagnostic criteria) and for prognostic notably in at risk of evolution patients with autoantibody-positive arthralgia. Risk biomarkers for rapid evolution or cardiovascular complications are also highly desirable. Monitoring biomarkers would be useful in predicting relapse. Finally, predictive biomarkers for therapy outcome would allow tailoring therapy to the individual. Increasing numbers of cytokines have been involved in RA pathology. Many have the potential as biomarkers in RA especially as their clinical utility is already established in other diseases and could be easily transferable to rheumatology. We will review the current knowledge's relation to cytokine used as biomarker in RA. However, given the complexity and heterogeneous nature of RA, it is unlikely that a single cytokine may provide sufficient discrimination; therefore multiple biomarker signatures may represent more realistic approach for the future of personalised medicine in RA.
类风湿关节炎（RA）是一种复杂的疾病，其发展过程是一系列常被称为疾病连续体的事件。对于RA的诊断，新型生物标志物的开发仍有必要（即便将抗环瓜氨酸肽抗体（ACPA）纳入美国风湿病学会（ACR）/欧洲抗风湿病联盟（EULAR）2010年诊断标准已取得进展），而对于预后评估，尤其是对于有病情进展风险的自身抗体阳性关节痛患者，新型生物标志物的开发也很有必要。快速进展或心血管并发症的风险生物标志物同样非常需要。监测生物标志物有助于预测病情复发。最后，治疗结果预测生物标志物将使治疗能够因人而异。越来越多的细胞因子与RA的病理过程有关。许多细胞因子有潜力成为RA中的生物标志物，特别是因为它们的临床应用在其他疾病中已经确立，并且可以很容易地应用于风湿病学。我们将综述目前与在RA中用作生物标志物的细胞因子相关的知识。然而，鉴于RA的复杂性和异质性，单一细胞因子不太可能提供足够的鉴别能力；因此，多种生物标志物特征可能代表了RA个性化医学未来更现实的方法。
